Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 3/20 | 0.43 |
| ▸ | AGXT | P21549 | 2/20 | 0.43 |
| ▸ | APP | P05067 | 7/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4257566 | 0.88 | CA1 (0.52) | CA1CA2IDO1AGXTAPP | |
| SCHEMBL4256434 | 0.79 | CA1 (0.53) | CA1CA2IDO1AGXTAPP | |
| SCHEMBL4258715 | 0.79 | CA1 (0.53) | CA1CA2IDO1AGXTAPP | |
| SCHEMBL2608864 | 0.78 | CA1 (0.62) | CA1CA2IDO1AGXTAPP | |
| SCHEMBL15292337 | 0.77 | CA1 (0.47) | CA1CA2IDO1AGXTAPP | |
| SCHEMBL15292334 | 0.77 | CA1 (0.47) | CA1CA2IDO1AGXTAPP | |
| SCHEMBL12474868 | 0.75 | SLC6A4 (0.61) | CA1CA2IDO1AGXTAPP | |
| SCHEMBL12697374 | 0.75 | SLC6A4 (0.61) | CA1CA2IDO1AGXTAPP | |
| SCHEMBL15831104 | 0.75 | CA1 (0.68) | CA1CA2IDO1AGXTAPP | |
| SCHEMBL4253460 | 0.73 | IDO1 (0.48) | CA1CA2IDO1AGXTAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009046098-A1 | NOVEL CYCLIC BORONATE INHIBITORS OF HCV REPLICATION | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-09 | — | — | WO | disclosed |